Publikationen 2015

Jurmeister P, Lenze D, Berg E, Mende S, Schäper F, Kellner U, Herbst H, Sers C, Budczies J, Dietel M, Hummel M, von Laffert M
Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Lung Cancer 2015; 87(2):122-9.
Jesinghaus M, Wolf T, Pfarr N, Muckenhuber A, Ahadova A, Warth A, Goeppert B, Sers C, Kloor M, Endris V, Stenzinger A, Weichert W.
Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer..
Am J Surg Pathol 2015; [Epub ahead of print]
Györffy B, Stelniec-Klotz I, Sigler C, Kasack K, Redmer T, Qian Y, Schäfer R.
Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. .
Oncotarget. 2015;

Publikationen 2014

Lienhard M, Grimm C, Morkel M, Herwig R, Chavez L
MEDIPS: genome-wide differential coverage analysis of sequencing data derived from DNA enrichment experiments.
Bioinformatics 2014; 30(2):284-6.
Riemer P, Sreekumar A, Reinke S, Rad R, Schäfer R, Sers C, Bläker H, Herrmann BG, Morkel M.
Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity..
Oncogene. 2014;
Relógio A, Thomas P, Medina-Pérez P, Reischl S, Bervoets S, Gloc E, Riemer P, Mang-Fatehi S, Maier B, Schäfer R, Leser U, Herzel H, Kramer A, Sers C.
Ras-mediated deregulation of the circadian clock in cancer..
PLoS Genet. 2014; 10(5)
Mamlouk S, Kalucka J, Singh RP, Franke K, Muschter A, Langer A, Jakob C, Gassmann M, Baretton GB, Wielockx B
Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development.
Int J Cancer 2014; 134(4):849-58.
Redmer T, Welte Y, Behrens D, Fichtner I, Przybilla D, Wruck W, Yaspo ML, Lehrach H, Schäfer R, Regenbrecht CR.
The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells..
PLoS One 2014; 9(5):e92596.

Publikationen - 2013

Dietel M, Jöhrens K, Laffert M, Hummel M, Bläker H, Müller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Cancer Gene Ther 2013; 20(4):211-21.
Mamlouk S, Wielockx B
Hypoxia-inducible factors as key regulators of tumor inflammation.
Int J Cancer 2013; 132(12):2721-9.
Gries J, Schumacher D, Arand J, Lutsik P, Markelova MR, Fichtner I, Walter J, Sers C, Tierling S.
Bi-PROF: bisulfite profiling of target regions using 454 GS FLX Titanium technology.
Epigenetics 2013; 8(7):765-71.
Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N.
Network quantification of EGFR signaling unveils potential for targeted combination therapy.
Mol Syst Biol. 2013; 9:673.
Franke K, Kalucka J, Mamlouk S, Singh RP, Muschter A, Weidemann A, Iyengar V, Jahn S, Wieczorek K, Geiger K, Muders M, Sykes AM, Poitz DM, Ripich T, Otto T, Bergmann S, Breier G, Baretton G, Fong GH, Greaves DR, Bornstein S, Chavakis T, Fandrey J, Gassmann M, Wielockx B.
HIF-1α is a protective factor in conditional PHD2-deficient mice suffering from severe HIF-2α-induced excessive erythropoiesis.
Blood. 2013; 121(8):1436-45.
Welte Y, Davies C, Schäfer R, Regenbrecht CR
Patient derived cell culture and isolation of CD133⁺ putative cancer stem cells from melanoma..
J Vis Exp. 2013; 73:e50200.
Pénzváltó Z, Tegze B, Szász AM, Sztupinszki Z, Likó I, Szendrői A, Schäfer R, Győrffy B.
Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines..
PLoS One. 2013; 8(3):e59503.
Malek A, Gyorffy B, Catapano CV, Schäfer R
Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation..
Cancer Gene Ther. 2013; 20(5):326-9.
Grimm C, Chavez L, Vilardell M, Farrall AL, Tierling S, Böhm JW, Grote P, Lienhard M, Dietrich J, Timmermann B, Walter J, Schweiger MR, Lehrach H, Herwig R, Herrmann BG, Morkel M.
DNA-methylome analysis of mouse intestinal adenoma identifies a tumour-specific signature that is partly conserved in human colon cancer.
PLoS Genet. 2013; 9(2):e1003250.

Publikationen- 2012

Győrffy B, Benke Z, Lánczky A, Balázs B, Szállási Z, Timár J, Schäfer R.
RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data..
Breast Cancer Res Treat. 2012; 132(3):1025-34.
Farrall AL, Riemer P, Leushacke M, Sreekumar A, Grimm C, Herrmann BG, Morkel M.
Wnt and BMP signals control intestinal adenoma cell fates.
Int J Cancer. 2012; 131(10):2242-52.
Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R.
Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.
Mol Syst Biol. 2012; 8:601.
Kuehnen P, Mischke M, Wiegand S, Sers C, Horsthemke B, Lau S, Keil T, Lee YA, Grueters A, Krude H.
An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity.
PLoS Genet. 2012; 8(3):e1002543.

Publikationen - 2011

Schäfer R, Sers C.
RAS oncogene-mediated deregulation of the transcriptome: From molecular signature to function.
Adv Enzyme Regul. 2011; 51(1):126-36.

Publikationen - 2010

Tchernitsa O, Kasajima A, Schäfer R, Kuban RJ, Ungethüm U, Györffy B, Neumann U, Simon E, Weichert W, Ebert MP, Röcken C.
Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.
J Pathol. 2010; 222(3):310-9.
Krech T, Thiede M, Hilgenberg E, Schäfer R and Jürchott K.
Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signalling pathway pertubations.
BMC Cancer 2010; 10:287.
Munkácsy G, Abdul-Ghani R, Mihály Z, Tegze B, Tchernitsa O, Surowiak P, Schäfer R, Györffy B.
PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.
Br J Cancer 2010; 102(2):361-8.
Nazarenko I, Jenny M, Gieseler C, Weisshaupt K, Sehouli J, Legewie S, Herbst L, Weichert W, Darb-Esfahani S, Dietel M, Schäfer R, Ueberall F, Sers C.
Atypical protein kinase C zeta exhibits a pro-apoptotic function in ovarian cancer.
Mol. Cancer Res. 2010; 8(6):913-934.
Wolkenhauer O, Auffray C, Baltrusch B, Blüthgen N, Byrne H, Cascante M, Ciliberto A, Dale T, Drasdo D, Fell D, Ferrell JEJr., Gallahan D, Gatenby R, Günther U, Harms BD, Herzel H, Junghanss C, Kunz M, van Leeuwen I, Lenormand P, Levi F, Linnebacher M, Lowengrub J, Maini PK, Malik A, Rateitschak K, Sansom O, Schäfer R, Schürrle K, Sers C, Schnell S, Shibata D, Tyson J, Vera J, White M, Zhivotovsky B, and Jaster R.
Systems biologists seek fuller integration of systems biology approaches in new cancer research programs.
Cancer Res. 2010; 70(1):12-3.
Györffy B, Schäfer R.
Biomarkers downstream of RAS: A search for robust transcriptional targets.
Curr Cancer Drug Targets 2010; 10(8):858-68.
Jürchott K, Kuban RJ, Krech T, Blüthgen N, Stein U, Walther W, Friese C, Kiełbasa SM, Ungethüm U, Lund P, Knösel T, Kemmner W, Morkel M, Fritzmann J, Schlag PM, Birchmeier W, Krueger T, Sperling S, Sers C, Royer HD, Herzel H, Schäfer R.
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway- dependent gene signatures in colorectal cancer cells.
PLoS Genet. 2010; 6(12):e1001231.

Publikationen - 2009

Blüthgen N, Legewie S, Kielbasa SM, Schramme A, Tchernitsa O, Keil J, Solf A, Vingron M, Schäfer R, Herzel H, Sers C.
A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts.
FEBS J 2009; 276(4):1024-35.
Sers C, Kuner R, Falk CS, Lund P, Sueltmann H, Braun M, Buness A, Ruschhaupt M, Conrad J, Mang-Fatehi S, Stelniec I, Krapfenbauer U, Poustka A, Schäfer R.
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.
Int J Cancer 2009; 125(7):1626-39.

Publikationen - 2008

Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O.
HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Int J Cancer 2008; 123(2):348-56.

Publikationen - 2007

Schäfer R, Schramme A, Tchernitsa OI, Sers C.
Oncogenic signaling pathways and deregulated target genes.
Recent Results Cancer Res. 2007; 176(7):24.
Nazarenko I, Schäfer R, Sers C.
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells.
J Cell Sci 2007; 120(8):1393-404.

Publikationen - 2006

Lund P, Weisshaupt K, Mikeska T, Jammas D, Chen X, Kuban RJ, Ungethüm U, Krapfenbauer U, Herzel HP, Schäfer R, Walter J, Sers C.
Oncogenic HRAS suppresses clusterin expression through promoter hypermethylation.
Oncogene 2006; 25(35):4890-903.

Publikationen - 2005

Lotz K, Kellner T, Heitmann M, Nazarenko I, Noske A, Malek A, Gontarewicz A, Schäfer R, Sers C.
Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.
Int J Cancer 2005; 116(6):894-902.

Publikationen - 2004

Tchernitsa OI, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, Lund P, Schwendel A, Rosenthal A, Schäfer R.
Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells.
Oncogene 2004; 23(26):4536-55.

Publikationen - 2002

Sers C, Husmann K, Nazarenko I, Reich S, Wiechen K, Zhumabayeva B, Adhikari P, Schröder K, Gontarewicz A, Schäfer R.
The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells.
Oncogene 2002; 25(21):2829-39.

Publikationen - 2000

Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A, Schäfer R.
A genome-wide survey of RAS transformation targets.
Nat Genet 2000; 24(2):144-52.